Terry Bromley Chosen to Lead Imbed Biosciences

Imbed Biosciences has a new leader—the company recently named Terry Bromley as its CEO.

Bromley has more than 30 years of experience in the medical device, regenerative medicine, and wound and skin markets. His background will be conducive in fostering the company’s growth and mission to transform soft tissue repair through advanced technologies.

“Terry brings a wealth of commercial leadership experience in the wound and skin care sector, delivering innovation and building high-performing teams. This appointment marks a pivotal moment for our company as we strive to revolutionize infection solutions and accelerate wound care,” Imbed Biosciences Founder/Chief Scientific Officer Ankit Agarwal stated. “His expertise will be invaluable as we navigate the next phase of our company’s growth with our Microlyte Matrix technology platform. I’m excited to welcome Terry to the Imbed Biosciences family.”

Before joining Imbed Biosciences, Bromley was senior vice president, Commercial Operations and Global Sales, at AVITA Medical, where he led the company’s regenerative tissue commercial teams and expanded both U.S. and global commercial capabilities. Previously, as senior vice president and general manager at Crawford Healthcare, he established the U.S. business unit and drove it to full commercialization in the wound and skin care markets. His earlier roles include senior director of Marketing and Business Development, Healthcare Protective Products Division at Emergent BioSolutions, and nearly two decades at ConvaTec, a Bristol Myers Squibb unit, where he advanced through various leadership positions, leading strategic portfolio and commercialization initiatives for ConvaTec’s wound and burn care technologies.

“Imbed’s differentiated platform technology uniquely positions the company to make a meaningful impact on the healthcare industry,” Bromley said. “I’m excited about this opportunity, and eager to collaborate with the team at Imbed. Together, we’ll drive the company’s growth in the wound care market and improve the lives of patients.”

Imbed Biosciences is a privately held medical device company developing and commercializing solutions to improve wound care. The company’s products on the market and in development combat local pain and infections in complex wounds using its patented Microlyte Matrix technology platform.